Insiders are accumulating shares before the big news!
Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced the completion of three executive hires and an expansion of its commercial operations in preparation for expected sales growth of its microRNA diagnostic assays, specifically its flagship product miRview® mets2. The Company recently announced a co-marketing agreement with Precision Therapeutics, Inc. for miRview® mets2, as well as a recent decision by Medicare to reimburse the miRview® mets2 assay.
Rosetta Genomics receives USPTO patent for Micrornas
Rosetta Genomics received a USPTO patent for Micrornas, described as polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
The 52 week trading range is $1.40 - $25.80
Big news will be announced shortly.
Stock is trading off the 52 week low with good news!
Short term price target on Rosetta Genomics Ltd. (ROSG) is $25.10
The genetics sector is the hottest sector in the markets!
Chart is strong accumulation is high and the stock keeps breaking new highs day after day, this stock is way over sold and buyers are here!
Rosetta Genomics Ltd. (ROSG)
Buyout target by the top three cell phone companies!! Insiders are buying early before the news!
Leap Wireless International Inc. (LEAP) -NasdaqGS
6.22 0.28(4.71%) 11:45AM EDT - Nasdaq Real Time Price!
Buy out price is around $16.00 a share! Offers are on the table!
Falcon Point Capital LLC says shareholders could see the value of their stakes doubling in a takeover from $4.96 a share yesterday, while Pivotal Research Group sees a deal driving the stock to $16.
Aug 14 - Standard & Poor's Ratings Services said today that it raised its
issue-level rating on the senior unsecured debt at Leap Wireless International
Inc. subsidiary Cricket Communications Inc. to 'B-' from 'CCC+' and
revised the recovery rating to '3' from '5'. The '3' recovery rating indicates
our expectations for meaningful (50%-70%) recovery in the event of a payment
default. (For the full recovery analysis, see the report on Leap, to be
published shortly on RatingsDirect.)
52wk Range: 4.28 - 11.30
She keeps going! New price target is $45.00 a share! Market potential is 47.5 billion!!!
Pluristem Therapeutics, Inc. (PSTI) -NasdaqCM
4.75 Aug 16, 4:00PM EDT|Pre-Market: 4.99 0.24 (5.05%) 8:51AM EDT - Nasdaq Real Time Price
Market potential of this biotech companies pipeline is 47.5 billion
Tired of missing the hottest stocks on Wall Street and missing those massive gains? The join our FREE newsletter today! We alert NASDAQ listed companies on the move not OTC and Pink Sheet Companies!
This stock will rise 300% and is now a buyout target from GOOGLE! New short term price target is $22.50 a share!
Velti Plc (VELT) -NasdaqGS
7.15 0.54(8.17%) 4:00PM EDT
The ad and marketing agency has been making acquisitions to position it for growth, and its purchase of CASEE, China's largest mobile ad exchange and network, sets it up for that market's own exponential growth trajectory.
Revenue grew 75% to $51.8 million.
Velti (VELT), the leading global provider of mobile marketing and advertising technology, today announced the addition of Harry Patz as Chief Revenue Officer to the Velti Executive team. Patz joins Velti after 20 years of experience at Microsoft Corporation, where he most recently served as Vice President of the Communications Sector North America for Mobile, Media Video, Cloud and Enterprise.
Velti has grown rapidly in the last two years, fueled by a successful U.S. public offering in 2011 and strategic acquisitions (including Mobile Interactive Group, Air2Web and CASEE) within the past 12 months. In March, the company announced 2011 revenues of $189.2 million-an increase of 63% over 2010. In May, the company announced Q1 2012 revenues at $51.8 million, which exceeded guidance and represented a 75% increase in revenue over Q1 2011. After further reviewing their recent financial reports, it appears that their internal organic growth rate was about 40% prior to several acquisitions. Considering that they also appear to have the potential to establish themselves as a monopolistic business, Durig Capital has selected it for early addition to our Monopoly Portfolio.
New Biotech Alert! (NDA) filing coming on or before 8/31/12 !!
DURECT Corporation (DRRX) -NasdaqGM
0.94 0.00(0.00%) 1:34PM EDT - Nasdaq Real Time Price
Talon Therapeutics, Inc. (TLON)
1.68 0.15 (9.80%) 3:59PM EDT
Trading 4 X the daily average volume today!
(FDA) approval coming in less than 18 days for their lead drug !
Short term price target is $4.50
Marqibo® (vincristine sulfate liposome injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin’s lymphoma (NHL) and ALL. Talon has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma.
More Details »
Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »
Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »
Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor.
I told you! get in now, heavy accumulation the FDA is approving this! They also have a very strong pipeline with all drugs in stage 2 already!
Stock is a buy!
We are very bullish on shares of Talon Therapeutics (TLON). We are placing a short term price target of $4.50 cents a share. Insiders are accumulating shares. The stock just broke another 52 week high today. They have a deep strong pipeline. The (FDA) will approve their lead drug in less than 18 days. The chart is very strong with heavy accumulation over the last 15 days.
Insiders are buying again today
Meeting will take place on or before 8/12/12 and will be good news
Company also has more news to announce.
Volume will pick up over the next 14 days as we get closer to PDUFA
We are right again! Big news is coming! Stock will rise 200%
Complete Genomics, Inc. (GNOM) -NasdaqGM
3.04 0.23(8.15%) 10:59 AM EDT - Nasdaq Real Time Price
New short term price target is $7.00!
If you short this stock you will lose your money!
Insiders are buying again today!
I was just digging into this whole situation with Vringo, Inc. (VRNG) -NYSE MKT
Here is what we have, (VRNG) owns a few patents and mobile platforms of it's own. Some of the people who used to work for Lycos started a new company IP/Engine, and innovate protect. They purchased Lycos patents related to search engines.
Google's revenue is based on this model and generates most of its revenue on this.
A private company merging with a public company
Market cap increase to 156 million with the combined new company. This merger closes this week on Thursday!
Court has already ruled in favor of (VRNG), no way Google will take them to court, if they loose there stock will drop more than 50%. They will need to settle, or buy them out.
(VRNG) also has lawsuits filed on AOL, target, and others who use Ad Sense.
New short term price target is $12.00
If they win their case or settle new short term price target would be $50.00
Let's Make Money.....Merger next week!
Vringo, Inc. (VRNG) -NYSE MKT
They will merge with a private company with a 150 million market cap, add that to their 56 million market cap new market cap is 206 million!
Stock is at $4.00 with a market cap of 56 million!
At 205 million stock will gap higher the following day!
Bullish court cases in favor of (VRNG) You will want to be a share holder before market close today!
Want to bet? Read the news that is out, and read my post, this is why its blowing past $3.00 you fool!
Read it and weep shorts! Not only are they offering shares to raise capital around $1.50 a share up up to 300 million!
This is very good news is it means it will not go Bankrupt! There is also some news as (AONE) just made the number one spot on the Threshold Short Listed and it is now flagged:)
That is also very good news as they will need to cover those shares at a much higher price now! They have now got them selves in a bad jam because it is shorted and also naked shorted which means the stock is going up!
The DOE will be granting additional funding shortly for a new project!
Stock is trading off the 52 week low, bad news already priced in and good news just released!
We are also now selling Fisker in the USA as of Friday!
Good news is also coming out next week! We are going to blow right through $3.00 a share!